Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 6/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14107103 | 1.00 | BDKRB2 (0.54) | BDKRB2OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL14265202 | 0.95 | BDKRB2 (0.51) | BDKRB2OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL14265229 | 0.87 | BDKRB2 (0.40) | BDKRB2 | |
| SCHEMBL14265228 | 0.83 | OPRL1 (0.40) | BDKRB2OPRM1OPRK1OPRL1 | |
| SCHEMBL14265243 | 0.82 | ACE (0.40) | BDKRB2 | |
| SCHEMBL14265240 | 0.78 | OPRL1 (0.39) | BDKRB2OPRM1OPRK1OPRL1 | |
| SCHEMBL15937192 | 0.74 | BDKRB2 (0.38) | BDKRB2 | |
| SCHEMBL15255699 | 0.73 | MMP1 (0.35) | BDKRB2HSD11B1 | |
| SCHEMBL19852817 | 0.73 | TSHR (0.41) | BDKRB2 | |
| SCHEMBL12658975 | 0.71 | GRIN1 (0.38) | OPRM1OPRD1OPRK1OPRL1EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-03-13 | — | — | US | disclosed |
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | MYD88, TLR4, TLR6 | BDKRB2 1724/4885OPRM1 1996/4885OPRD1 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.